The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Despite advancements in treatment options for relapsed or refractory multiple myeloma (MM), heavily pretreated patients continue to face significant clinical challenges, according to
Six poster winners were announced during Poster Session and Reception on Wednesday, September 4, at the Twelfth Annual Meeting of the Society of
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for myelodysplastic neoplasms (MDS) to recommend imetelstat for treating symptomatic anemia
Belantamab mafodotin, bortezomib, and dexamethasone (BVd) treatment showed “significant benefit” in progression-free survival (PFS) when compared with daratumumab, bortezomib, and dexamethasone (DVd) in
In this video interview from the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO), Bijal Shah, MD, of the Moffitt Cancer
The US Food and Drug Administration (FDA) has approved epcoritamab-bysp (EPKINLY) for the treatment of adults with relapsed or refractory follicular lymphoma after
The US Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for
https://youtu.be/xP3dZWHtfKs In this video filmed at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024), Hagop Kantarjian,MD, professor and chair
Hagop Kantarjian, MD, professor and chair in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, sits down with
